A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation

NCT01955616 | Terminated Phase 2

• 1 other identifier: RM-131-007
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 13

Brief Summary

The purpose of this study, called MOVE-PD, is to investigate how individuals with Parkinson's disease (PD) and chronic constipation (CC) respond to RM-131 as compared to placebo. The study will look at how well RM-131 affects the frequency of spontaneous bowel movements over a 14-day period. The study will also evaluate the safety and tolerability of the study drug and evaluate whether the study drug relieves the uncomfortable GI symptoms related to chronic constipation in patients who are unsatisfied with other therapies they have tried for constipation.

Conditions

Parkinson's Disease

Keywords

Parkinson's disease, chronic constipation

Outcome Measures

Primary Outcomes (1)

• Investigate the effects of treatment with RM-131 for 14 days on the frequency of spontaneous bowel movements (SBMs) when administered to patients with Parkinson's Disease (PD) and Chronic Constipation (CC)

  Screening through Day 28

Secondary Outcomes (3)

• Evaluate the safety and tolerability of multiple doses of RM-131 when administered to patients with PD and CC

  Screening through Day 28

• Effect of RM-131 on stool frequency as measured by complete spontaneous bowel movements, stool consistency, straining, completeness of evacuation, abdominal pain, and global patient reported outcomes of severity of constipation and overall relief.

  Screening through Day 28

• Assess symptoms of Parkinson's disease using the Unified Parkinson Disease Rating Scale (UPDRS)

  Screening through Day 28

Other Outcomes (3)

• Assess the effect of RM-131 on gastroparesis symptoms

  Screening through Day 28

• Time to first bowel movement (BM)

  Screening through Day 28

• Area under the concentration versus time curve of RM-131 will be measured

  Screening through Day 28

Study Arms (2)

RM-131

ACTIVE COMPARATOR

RM-131 100 µg by subcutaneous injection daily in the morning

Drug: RM-131

Placebo

PLACEBO COMPARATOR

by subcutaneous injection daily in the morning

Drug: Placebo

Interventions

RM-131 DRUG

Also known as: Ghrelin receptor agonist, relamorelin

RM-131

Placebo DRUG

Placebo

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Able to provide written informed consent and be willing and able to comply with study procedures.
• Diagnosis of Parkinson's disease
• Diagnosis of chronic constipation (CC), including experiencing constipation for \~12 or more weeks in the preceding 12 months.
• Regular treatment for chronic constipation during the last 6 months, and dissatisfaction with current treatment for CC, after treatment with at least 2 regimens for constipation (see note at end of this section).
• Stable medication history defined as no changes in regimen for at least 2 weeks prior to the baseline period
• Body mass index of 18-40 kg/m2
• Mini-mental status exam (at screening) ≥26
• Female patients must have negative serum or urine pregnancy tests and must not be lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. A vasectomized partner will be allowed as one in conjunction with another single-barrier method.
• Female patients unable to bear children must have this documented in the case report form(i.e., tubal ligation, hysterectomy, or post-menopausal \[defined as a minimum of one year since the last menstrual period\]). Post-menopausal status will be confirmed by follicle stimulating hormone (FSH) in women less than 60 years of age
• Note the following medications are allowed:
• Selective serotonin reuptake inhibitor (SSRI), SNRI, and tricyclic antidepressants are permissible at stable doses. All medications shall be reviewed and dis/approved by the investigator on a case-by-case basis.
• Benzodiazepines are permissible at stable doses
• Stable doses of antacids, NSAIDS, Cox-2 inhibitors, calcium supplements, thyroid replacement, estrogen replacements, low-dose aspirin for cardioprotection, and birth control (but with adequate back up contraception as drug interactions with birth control have not been conducted) are permissible
• Dopamine agonists and amantadine allowed if on a stable dose
• Deep brain stimulation is allowed.

You may not qualify if:

• Unable or unwilling to provide informed consent or to comply with study procedures
• Diagnosis of secondary constipation beyond that of Parkinson's disease
• Structural or metabolic diseases that affect the GI system
• Unable to withdraw the following medications 48 hours prior to the baseline period and throughout the study (except as protocol defined rescue medications; see below):
• Medications that alter GI transit including laxatives, prokinetics, erythromycin, narcotics, and anti-cholinergics (except as protocol defined rescue medications).
• GABAergic agents
• Drugs with a low therapeutic index, such as warfarin, digoxin, anti-seizure medications
• NOTE: Parkinson's disease therapies are allowed. Exceptions for Parkinson's disease medications include:
• Cogentin (benztopine), Artane (trihexyphenidyl), and apomorphone are excluded
• History of recent major surgery (within 60 days of screening)
• Acute or chronic illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the patient or obscure interpretation of laboratory test results or interpretation of study data such as frequent angina, Class III or IV congestive heart failure, moderate impairment of renal or hepatic function, poorly controlled diabetes, etc.
• History of symptomatic orthostatic hypotension or significant history of dizziness
• History of hypersensitivity to mannitol which is an ingredient of both active and placebo study medications
• Any clinically significant abnormalities on screening laboratories or physical examination as determined by the Investigator
• Abnormal 12-lead electrocardiogram (ECG), including evidence of acute myocardial or subendocardial ischemia and clinically significant arrhythmias or conduction abnormalities (including prolonged QTc \> 500 msec) or abnormal blood pressure at screening except minor deviations deemed to be of no clinical significance by the Investigator

Sponsors & Collaborators

• Motus Therapeutics, Inc.: lead
• Michael J. Fox Foundation for Parkinson's Research: collaborator

Study Sites (13)

University of Southern California

Los Angeles, California, United States

Location

Colorado Neurological Institute

Englewood, Colorado, United States

Location

University of Florida Ctr for Movement Disorders & Neurorestoration

Gainesville, Florida, United States

Location

Emory University, Wesley Woods Health Center

Atlanta, Georgia, United States

Location

Georgia Regents University

Augusta, Georgia, United States

Location

University of Iowa Hospitals, Movement Disorders Div, Dept of Neurology

Iowa City, Iowa, United States

Location

Michigan State University

East Lansing, Michigan, United States

Location

Henry Ford West Bloomfield Hospital

West Bloomfield, Michigan, United States

Location

Atlantic Neuroscience

Summit, New Jersey, United States

Location

University of Rochester

Rochester, New York, United States

Location

University of Toledo Medical Center

Toledo, Ohio, United States

Location

Movement Disorders Program & The Parkinson's Center of Oregon

Portland, Oregon, United States

Location

University of Pennsylvania, Penn Neurological Institute

Philadelphia, Pennsylvania, United States

Location

MeSH Terms

Conditions

Parkinson Disease

Interventions

relamorelin

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Study Officials

• Ronald Pfeiffer, MD

  Parkinson's Study Group

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 25, 2013
• First Posted: October 7, 2013
• Study Start: September 1, 2013
• Primary Completion: May 1, 2015
• Study Completion: September 1, 2015
• Last Updated: September 23, 2016

Record last verified: 2016-09

Locations

US (13)